Ex Vivo Expanded and Activated Natural Killer Cells Prolong the Overall Survival of Mice with Glioblastoma-like Cell-Derived Tumors

被引:9
|
作者
Shida, Yoichi [1 ]
Nakazawa, Tsutomu [1 ,2 ]
Matsuda, Ryosuke [1 ]
Morimoto, Takayuki [1 ]
Nishimura, Fumihiko [1 ]
Nakamura, Mitsutoshi [1 ,3 ]
Maeoka, Ryosuke [1 ]
Yamada, Shuichi [1 ]
Nakagawa, Ichiro [1 ]
Park, Young-Soo [1 ]
Yasukawa, Motoaki [4 ,5 ]
Tojo, Takashi [4 ,6 ]
Tsujimura, Takahiro [3 ]
Nakase, Hiroyuki [1 ]
机构
[1] Nara Med Univ, Dept Neurosurg, Kashihara, Nara 6348521, Japan
[2] Grandsoul Res Inst Immunol Inc, Uda, Nara 6332221, Japan
[3] Clin Grandsoul Nara, Uda, Nara 6332221, Japan
[4] Nara Med Univ, Dept Thorac Surg, Kashihara, Nara 6348521, Japan
[5] Osaka Kaisei Hosp, Dept Surg, Yodogawa, Osaka 5320003, Japan
[6] Saiseikai Chuwa Hosp, Dept Thorac Surg, Sakurai, Nara 6330054, Japan
关键词
PD-1; PD-L1; NK cell; glioblastoma; NEWLY-DIAGNOSED GLIOBLASTOMA; DELTA-T CELLS; ADJUVANT TEMOZOLOMIDE; PD-L1; EXPRESSION; NK CELLS; IMMUNOTHERAPY; THERAPY; RADIOTHERAPY; CONCOMITANT; PATTERNS;
D O I
10.3390/ijms22189975
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Glioblastoma (GBM) is the leading malignant intracranial tumor and is associated with a poor prognosis. Highly purified, activated natural killer (NK) cells, designated as genuine induced NK cells (GiNKs), represent a promising immunotherapy for GBM. We evaluated the anti-tumor effect of GiNKs in association with the programmed death 1(PD-1)/PD-ligand 1 (PD-L1) immune checkpoint pathway. We determined the level of PD-1 expression, a receptor known to down-regulate the immune response against malignancy, on GiNKs. PD-L1 expression on glioma cell lines (GBM-like cell line U87MG, and GBM cell line T98G) was also determined. To evaluate the anti-tumor activity of GiNKs in vivo, we used a xenograft model of subcutaneously implanted U87MG cells in immunocompromised NOG mice. The GiNKs expressed very low levels of PD-1. Although PD-L1 was expressed on U87MG and T98G cells, the expression levels were highly variable. Our xenograft model revealed that the retro-orbital administration of GiNKs and interleukin-2 (IL-2) prolonged the survival of NOG mice bearing subcutaneous U87MG-derived tumors. PD-1 blocking antibodies did not have an additive effect with GiNKs for prolonging survival. GiNKs may represent a promising cell-based immunotherapy for patients with GBM and are minimally affected by the PD-1/PD-L1 immune evasion axis in GBM.
引用
收藏
页数:14
相关论文
共 50 条
  • [1] Characterization of natural killer and natural killer-like T cells derived from ex vivo expanded and activated cord blood mononuclear cells: Implications for adoptive cellular immunotherapy
    Ayello, Janet
    van de Ven, Carmella
    Cairo, Evan
    Hochberg, Jessica
    Baxi, Laxmi
    Satwani, Prakash
    Cairo, Mitchell S.
    EXPERIMENTAL HEMATOLOGY, 2009, 37 (10) : 1216 - 1229
  • [2] Therapeutic Anti-KIR Antibody of 1-7F9 Attenuates the Antitumor Effects of Expanded and Activated Human Primary Natural Killer Cells on In Vitro Glioblastoma-like Cells and Orthotopic Tumors Derived Therefrom
    Maeoka, Ryosuke
    Nakazawa, Tsutomu
    Matsuda, Ryosuke
    Morimoto, Takayuki
    Shida, Yoichi
    Yamada, Shuichi
    Nishimura, Fumihiko
    Nakamura, Mitsutoshi
    Nakagawa, Ichiro
    Park, Young-Soo
    Tsujimura, Takahiro
    Nakase, Hiroyuki
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (18)
  • [3] Purified ex vivo expanded and activated human Natural Killer cells efficiently kill glioblastoma cells in a dose- and donor-dependent manner
    Kmiecik, Justyna
    Navarro, Andrea Gras
    Enger, Per O.
    Zelkowski, Mateusz
    Zimmer, Jacques
    Enger, Martha Chekenya
    CANCER RESEARCH, 2013, 73 (08)
  • [4] Efficacy of ex vivo activated and expanded natural killer cells and T lymphocytes for colorectal cancer patients
    Subramani, Baskar
    Pullai, Chithra Ramanathan
    Krishnan, Kohila
    Sugadan, Sheela Devi
    Deng, Xuewen
    Hiroshi, Terunuma
    Ratnavelu, Kananathan
    BIOMEDICAL REPORTS, 2014, 2 (04) : 505 - 508
  • [5] Highly Activated Ex Vivo-expanded Natural Killer Cells in Patients With Solid Tumors in a Phase I/IIa Clinical Study
    Nagai, Kazuhiro
    Harada, Yui
    Harada, Hiroshi
    Yanagihara, Katsunori
    Yonemitsu, Yoshikazu
    Miyazaki, Yasushi
    ANTICANCER RESEARCH, 2020, 40 (10) : 5687 - 5700
  • [6] Cytokine levels in ex-vivo expanded cord blood-derived natural killer (NK) cells
    Barak, V
    Condiotti, R
    Zakai, YB
    Nagler, A
    EUROPEAN CYTOKINE NETWORK, 1998, 9 (03) : 422 - 422
  • [7] Targeted immune cell therapy for hepatocellular carcinoma using expanded liver mononuclear cell-derived natural killer cells
    Hu, Xin
    Shui, Yifang
    Shimizu, Seiichi
    Sakamoto, Seisuke
    Kasahara, Mureo
    Okada, Seiji
    Guo, Wen-Zhi
    Fujino, Masayuki
    Li, Xiao-Kang
    NEOPLASIA, 2024, 58
  • [8] Ex vivo-expanded highly purified natural killer cells in combination with temozolomide induce antitumor effects in human glioblastoma cells in vitro
    Tanaka, Yoshitaka
    Nakazawa, Tsutomu
    Nakamura, Mitsutoshi
    Nishimura, Fumihiko
    Matsuda, Ryosuke
    Omoto, Koji
    Shida, Yoichi
    Murakami, Toshiharu
    Nakagawa, Ichiro
    Motoyama, Yasushi
    Morita, Hiromichi
    Tsujimura, Takahiro
    Nakase, Hiroyuki
    PLOS ONE, 2019, 14 (03):
  • [9] Impact Of Elotuzumab Therapy On Circulating and Ex Vivo Activated/Expanded Autologous Natural Killer (Auto-ENK) Cell Activity
    Szmania, Susann
    Greenway, Amy D.
    Lingo, Joshuah D.
    Stone, Katie
    Khan, Junaid
    Garg, Tarun K.
    Petty, Nathan M.
    Panozzo, Susan B.
    Woods, Emily
    Warden, Jessica
    Epstein, Joshua
    Barlogie, Bart
    van Rhee, Frits
    BLOOD, 2013, 122 (21)
  • [10] Natural killer cells expanded in vivo or ex vivo with IL-15 overcomes the inherent susceptibility of CAST mice to lethal infection with orthopoxviruses
    Earl, Patricia L.
    Americo, Jeffrey L.
    Moss, Bernard
    PLOS PATHOGENS, 2020, 16 (04)